| Pharmaceutical Information |
| Drug Name |
Cabazitaxel |
| Drug ID |
BADD_D00328 |
| Description |
Cabazitaxel is an anti-neoplastic used with the steroid medicine prednisone. Cabazitaxel is used to treat people with prostate cancer that has progressed despite treatment with docetaxel. Cabazitaxel is prepared by semi-synthesis with a precursor extracted from yew needles (10-deacetylbaccatin III). It was approved by the U.S. Food and Drug Administration (FDA) on June 17, 2010. |
| Indications and Usage |
For treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen. |
| Marketing Status |
approved |
| ATC Code |
L01CD04 |
| DrugBank ID |
DB06772
|
| KEGG ID |
D09755
|
| MeSH ID |
C552428
|
| PubChem ID |
9854073
|
| TTD Drug ID |
D02HSB
|
| NDC Product Code |
54893-0016; 61200-101; 0024-5824; 47848-044; 63126-909; 55111-962; 68554-0080 |
| UNII |
51F690397J
|
| Synonyms |
cabazitaxel | kabazitaxel | Jevtana |
|
| Chemical Information |
| Molecular Formula |
C45H57NO14 |
| CAS Registry Number |
183133-96-2 |
| SMILES |
CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)
O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)OC)C)OC |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
